Hologic gets CE Mark for COVID-19 test

By LabPulse.com staff writers

July 15, 2021 -- Hologic announced it has received the CE Mark for the use of saliva samples with its Aptima SARS-CoV-2 assay in Europe. The assay also has the CE Mark for use with nasopharyngeal and nasal swabs as well as additional specimen types.

The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the genetic material of the pathogen causing COVID-19 and runs on the fully automated Panther system, Hologic said.

The company said it has expanded manufacturing capability to produce Aptima tests in large quantities and has shipped more than 100 million Aptima COVID-19 tests globally since the spring of 2020. Approximately 2,600 Panther systems have been installed in clinical diagnostic laboratories around the world, Hologic added.

Hologic receives CE Mark for CMV detection assay
Hologic has received the CE Mark for its molecular assay to quantify human cytomegalovirus (CMV). The Aptima CMV Quant assay is the company's first test...
Ink dries on Hologic's deal to buy Mobidiag
Hologic announced the completion of its $808 million acquisition of biotechnology company Mobidiag. The Finnish-French company develops near-patient,...
Hologic's growth continues in Q2
Hologic has continued to post significant increases in revenue, with revenues doubling in the company's second quarter. The growth was driven primarily...
Hologic acquires Mobidiag for $795M
Hologic announced it has agreed to acquire Mobidiag, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests...
Market for COVID-19 diagnostics to hit $38B by year end
As the unfortunate milestone of one full year of the global COVID-19 pandemic worldwide is reached, the diagnostic industry has been changed, perhaps...

Copyright © 2021 LabPulse.com

Last Updated ls 7/15/2021 2:43:11 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current